Moderna's mRESVIA has secured FDA approval to protect adults ages 60 years and older from lower respiratory tract disease ...

One of the biggest take-aways from our report is that LGBTQ+ people are probably at higher risk for cancer, yet experience ...

While Canada’s largest vaccine manufacturing facility has opened its doors and is flying the Sanofi flag, another of the ...

Gilead Sciences is drawing back the curtain on the Trodelvy lung cancer data that previously caused a 10% slide in the ...

In the span of half a year, Gilead’s Trodelvy has flopped a second phase 3 trial. | Following a high-profile lung cancer ...

Takeda is planning more than 600 layoffs in Massachusetts. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to show an overall survival benefit in a lung cancer study. | Takeda is planning more than ...

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytruda ...

In the years since gaining an initial FDA approval for Breyanzi, Bristol Myers Squibb has worked hard to expand the reach of ...

The United States Department of Health and Human Services has expanded its avian flu pandemic preparedness partnership with ...

In the U.S., the FDA has pushed its decision date back three months to Sept. 27. Meanwhile in Europe, the Committee for Medicinal Products for Human Use (CHMP) has recommended Dupixent for approval to ...

With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed ...

With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much ...